Enveric Biosciences (NASDAQ:ENVB) Stock Price Up 1.9% – Here’s What Happened

Enveric Biosciences, Inc. (NASDAQ:ENVB) was up 1.9% during mid-day trading on Monday . The company traded as high as $1.6299 and last traded at $1.60. 83,980 shares were traded during trading, a decline of 25% from the average daily volume of 111,233 shares. The stock had previously closed at $1.57.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Friday, July 17th. Wall Street Zen upgraded shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Enveric Biosciences presently has a consensus rating of “Sell”.

Enveric Biosciences Trading Up 1.9%

The company has a 50 day simple moving average of $1.54 and a 200-day simple moving average of $2.26. The stock has a market cap of $5.89 million, a price-to-earnings ratio of -0.07 and a beta of 1.13.

Enveric Biosciences (NASDAQ:ENVB) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.08) earnings per share for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.